In another trial, an autologous EPHA2-targeted CAR-DC vaccine loaded with TP53 mutant peptide (TP53-EPHA-2-CAR-DC) combined with an anti-PD-1 antibody/anti-CTLA4 antibody is used in patients with locally advanced/metastatic solid tumors or relapsed/refractory lymphoma (NCT05631886) [188]. The gene discussed is TP53; the disease is lymphoma.